DrugsControl Media Services

News Detail

Encorafenib, Binimetinib and Cetuximab combo improves survival period for bowel cancer patients (07-07-2019)

London, 6 July 2019: A targeted three-drug combination therapy resulted in median overall survival of nine months for patients with advanced bowel cancer compared to 5.4 months for current standard-of-care treatment, showed the results of a phase-3 clinical trial.

View Details

Source : ET Healthworld

Related News